HC Wainwright initiated coverage on shares of Perspective Therapeutics (NYSE:CATX - Get Free Report) in a report issued on Thursday, Marketbeat.com reports. The brokerage set a "buy" rating and a $10.00 price target on the stock. HC Wainwright's price target points to a potential upside of 284.62% from the company's previous close. HC Wainwright also issued estimates for Perspective Therapeutics' Q4 2024 earnings at ($0.24) EPS, Q1 2025 earnings at ($0.27) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.33) EPS and FY2025 earnings at ($1.19) EPS.
A number of other equities analysts have also commented on the stock. Bank of America lowered shares of Perspective Therapeutics from a "buy" rating to a "neutral" rating and cut their price objective for the stock from $24.00 to $5.00 in a report on Monday, November 25th. Scotiabank began coverage on shares of Perspective Therapeutics in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 target price on the stock. Oppenheimer cut their target price on shares of Perspective Therapeutics from $22.00 to $16.00 and set an "outperform" rating on the stock in a research note on Friday, November 22nd. Brookline Capital Management upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a research note on Monday, March 10th. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $16.00 target price on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, Perspective Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $14.56.
Read Our Latest Report on Perspective Therapeutics
Perspective Therapeutics Stock Performance
Shares of NYSE:CATX traded up $0.01 during midday trading on Thursday, hitting $2.60. 412,031 shares of the company's stock traded hands, compared to its average volume of 983,650. The firm's fifty day moving average price is $3.14 and its two-hundred day moving average price is $7.20. Perspective Therapeutics has a twelve month low of $2.32 and a twelve month high of $19.05.
Institutional Trading of Perspective Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. lifted its stake in Perspective Therapeutics by 221.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company's stock valued at $5,788,000 after purchasing an additional 298,778 shares during the last quarter. State Street Corp lifted its stake in Perspective Therapeutics by 119.6% during the third quarter. State Street Corp now owns 2,190,239 shares of the company's stock valued at $29,240,000 after purchasing an additional 1,192,812 shares during the last quarter. Janus Henderson Group PLC lifted its stake in Perspective Therapeutics by 8.0% during the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company's stock valued at $64,014,000 after purchasing an additional 355,685 shares during the last quarter. FMR LLC lifted its stake in Perspective Therapeutics by 3,994.9% during the third quarter. FMR LLC now owns 5,504,822 shares of the company's stock valued at $73,489,000 after purchasing an additional 5,370,392 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in Perspective Therapeutics by 1,302.7% during the third quarter. BNP Paribas Financial Markets now owns 47,565 shares of the company's stock valued at $635,000 after purchasing an additional 44,174 shares during the last quarter. 54.66% of the stock is owned by institutional investors and hedge funds.
About Perspective Therapeutics
(
Get Free Report)
Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.
Further Reading
Before you consider Perspective Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Perspective Therapeutics wasn't on the list.
While Perspective Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
